Amazon Pharmacy Begins Offering Wegovy Pill — Update
By Nicholas G. Miller
Amazon Pharmacy has started offering Novo Nordisk's Wegovy weight-loss pill, joining other pharmacies in selling the recently approved tablet poised to shake up the GLP-1 market.
Customers with commercial insurance will pay a minimum of $25 for a one-month supply, while the cost for those without insurance starts at $149 a month, Amazon said.
The Food and Drug Administration approved the oral pill form of Wegovy, a GLP-1, last month. This week, Novo Nordisk said the pill was now widely available in the U.S. in 70,000 pharmacies such as CVS and Costco, and telehealth providers including Ro, LifeMD, Weight Watchers, NovoCare Pharmacy and GoodRx, among others.
The once-daily pill is the first GLP-1 weight-loss pill to hit the market. Eli Lilly recently filed for U.S. approval of its own GLP-1 weight-loss tablet. Analysts have said that while oral forms may be less effective than GLP-1 injections, they could expand the weight-loss drug market by lowering the cost and attracting needle-averse patients.
As part of deals struck with the Trump administration late last year, Novo Nordisk and Eli Lilly agreed to make their weight-loss pills available for direct-to-consumer purchase at starting doses of $149 a month. The Food and Drug Administration has granted special new vouchers to Lilly and Novo Nordisk intended to speed up the agency's review of the weight-loss pills.
Write to Nicholas G. Miller at nicholas.miller@wsj.com
(END) Dow Jones Newswires
January 09, 2026 09:55 ET (14:55 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
3 Stocks to Sell and 3 Stocks to Buy for October
The 10 Best Companies to Invest in Now
3 Stocks to Invest In With More Room to Run
14 Elite Funds and ETFs, and 5 Popular Funds That Just Missed the Mark
United States